Using nasal antiseptic to prevent Candida auris infections
Impact of Nasal Antisepsis on Candida Auris Colonization
This study is testing if a nasal antiseptic can help prevent Candida auris infections in people who have a history of this infection while they are in the hospital.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Rush University Medical Center Academic / other |
| Locations | 3 sites (Chicago, Illinois and 2 other locations) |
| Trial ID | NCT06282510 on ClinicalTrials.gov |
What this trial studies
This trial evaluates the effectiveness of 10% povidone iodine as an intranasal antiseptic to reduce colonization and environmental contamination of Candida auris. Participants with a history of C. auris colonization will be randomly assigned to receive either the antiseptic treatment or no treatment. The study will take place in two long-term acute care hospitals and one acute care hospital in the Chicago area, with participants monitored over a series of visits during their hospitalization. The goal is to determine if this widely used antiseptic can effectively prevent C. auris infections in at-risk populations.
Who should consider this trial
Good fit: Ideal candidates are patients with a history of Candida auris colonization or infection currently hospitalized in a participating facility.
Not a fit: Patients with severe allergies to iodine-based products, those who are pregnant or breastfeeding, and non-English speakers may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of Candida auris infections in vulnerable patient populations.
How similar studies have performed: Previous studies have shown the effectiveness of povidone iodine in decolonizing other pathogens, suggesting potential success for this novel application against C. auris.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * History of C. auris colonization or infection * Patient in a participating facility Exclusion Criteria: * History of severe allergy to iodine-based products, defined as anaphylaxis or rash * Currently breastfeeding or pregnant * Non-English language speaking
Where this trial is running
Chicago, Illinois and 2 other locations
- Rush University Medical Center — Chicago, Illinois, United States (Recruiting)
- RML Specialty Hospital — Chicago, Illinois, United States (Recruiting)
- RML Specialty Hospital — Hinsdale, Illinois, United States (Recruiting)
Study contacts
- Principal investigator: Mary K. Hayden, MD — Rush University Medical Center
- Study coordinator: Sarah E. Sansom, DO
- Email: sarah_e_sansom@rush.edu
- Phone: 3125636201
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.